Soft tissue, joint, and bone manifestations of AL amyloidosis - Clinical presentation, molecular features, and survival

被引:99
作者
Prokaeva, Tatiana
Spencer, Brian
Kaut, Maurya
Ozonoff, Al
Doros, Gheorghe
Connors, Lawreen H.
Skinner, Martha
Seldin, David C.
机构
[1] Boston Univ, Sch Med, Amyloid Treatment & Res Program, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Sch Publ Hlth, Boston, MA 02118 USA
来源
ARTHRITIS AND RHEUMATISM | 2007年 / 56卷 / 11期
关键词
D O I
10.1002/art.22959
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To characterize symptoms and signs of AL amyloidosis that may bring patients to the attention of rheumatologists, evaluate 19 V(L) gene usage in this subgroup of patients, and assess the impact of soft tissue and bone involvement and V(L) gene usage on survival. Methods. Clinical features of soft tissue and bone involvement were assessed in 191 patients with AL amyloidosis. V(L) gene sequencing was carried out to determine light-chain family, rate of somatic mutation, and evidence of antigen selection. The association of soft tissue and bone involvement with V(L) gene usage was assessed by logistic regression analysis, and survival time was analyzed using log rank tests and Cox regression models. Results. Soft tissue and bone involvement occurred in 42.9% of the patients, and 9.4% had dominant soft tissue and bone involvement. The most common manifestations were submandibular gland enlargement, macroglossia, and carpal tunnel syndrome. Dominant soft tissue and bone involvement was significantly associated with V(L)KI gene usage. Mutation rate and evidence of antigen selection in the V(L) genes were not found to be confounding factors, providing evidence against a contribution of autoimmunity in this type of AL amyloidosis. Survival time was initially longer in patients with dominant soft tissue and bone involvement than in patients with other dominant organ involvement; however, this difference diminished over time. Conclusion. Amyloid infiltration into soft tissue, joints, periarticular structures, and bones can bring patients with AL amyloidosis to the attention of rheumatologists. Recognition of the presenting symptoms is essential for accurate diagnosis and appropriate treatment, since the long-term outlook for untreated patients with dominant soft tissue And bone involvement is not better than that for patients with other dominant features of AL amyloidosis.
引用
收藏
页码:3858 / 3868
页数:11
相关论文
共 51 条
[1]   Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL) [J].
Abraham, RS ;
Geyer, SM ;
Price-Troska, TL ;
Allmer, C ;
Kyle, RA ;
Gertz, MA ;
Fonseca, R .
BLOOD, 2003, 101 (10) :3801-3808
[2]  
Axelsson U, 1970, J Bone Joint Surg Br, V52, P717
[3]  
Ben Ghorbel I, 1999, REV MED INTERNE, V20, P1037
[4]  
Bukhari M, 1997, BRIT J RHEUMATOL, V36, P494
[5]   Amyloid myopathy: Characteristic features of a still underdiagnosed disease [J].
Chapin, JE ;
Kornfeld, M ;
Harris, A .
MUSCLE & NERVE, 2005, 31 (02) :266-272
[6]   The tropism of organ involvement in primary systemic amyloidosis:: contributions of Ig VL germ line gene use and clonal plasma cell burden [J].
Comenzo, RL ;
Zhang, Y ;
Martinez, C ;
Osman, K ;
Herrera, GA .
BLOOD, 2001, 98 (03) :714-720
[7]   Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application [J].
Comenzo, RL ;
Michelle, D ;
LeBlanc, M ;
Wally, J ;
Zhang, Y ;
Kica, G ;
Karandish, S ;
Arkin, CF ;
Wright, DG ;
Skinner, M ;
McMannis, J .
TRANSFUSION, 1998, 38 (01) :60-69
[8]  
CURRAN JF, 1983, CLIN ORTHOP RELAT R, P27
[9]   Treatment of AL-amyloidosis with dexamethasone plus alpha interferon [J].
Dhodapkar, MV ;
Jagannath, S ;
Vesole, D ;
Munshi, N ;
Naucke, S ;
Tricot, G ;
Barlogie, B .
LEUKEMIA & LYMPHOMA, 1997, 27 (3-4) :351-356
[10]   Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis [J].
Dispenzieri, A ;
Lacy, MQ ;
Rajkumar, SV ;
Geyer, SM ;
Witzig, TE ;
Fonseca, R ;
Lust, JA ;
Greipp, PR ;
Kyle, RA ;
Gertz, MA .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2003, 10 (04) :257-261